Trevena, Inc.: Series B $35M

Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Cardiology, X - G-Protein, X - Pain, XX - PA

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

Aug

2010

TriVascular, Inc.: Series C $60M

Posted in I - Series C, Q - 3Q10, R - WEST, X - Device (Aneurysm), XX - CA

TriVascular (Santa Rosa, CA) a commercial-stage medical device company focused on endovascular repair devices for the treatment of abdominal aortic aneurysms, closed a $60M Series C financing. Participants include Pinnacle Ventures, New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.

Jul

2010

Liquidia Technologies, Inc.: Series C $5M

Posted in I - Series C, Q - 2Q10, R - SOUTH EAST, X - Device (Delivery), X - Vaccines, XX - NC

Liquidia Technologies (Research Triangle Park, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $5M Series C financing, bringing the total round to $25M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside, Firelake Capital and PPD

Jun

2010

Predictive Biosciences, Inc.: Series C $25M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Device (Diagnostic), X - Oncology, XX - MA

Predictive Biosciences (Lexington, MA) a commercial-stage molecular diagnostic company focused on oncology assays, closed a $25M Series C financing. Participants ProQuest Investments, Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Jun

2010

Anulex Technologies, Inc.: Series E $18.3M

Posted in I - Series E, Q - 2Q10, R - MID WEST, X - Device (Spine), XX - MN

Anulex Technologies (Minnetonka, MN) a commercial-stage medical device company focused on herniated discectomy procedures, closed a $18.3M Series E financing. Participants include Hatteras Late Stage VC Fund, Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.

May

2010

Tesaro, Inc.: Series A $60M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Oncology, XX - MA

Tesaro (Boston, MA) a preclinical-stage biopharmaceutical company focused on oncology therapeutics, closed a $60M Series A financing. Participants include New Enterprise Associates.

Apr

2010

Liquidia Technologies, Inc.: Series C $13M

Posted in I - Series C, Q - 1Q10, R - SOUTH EAST, X - Device (Delivery), X - Vaccines, XX - NC

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.

Mar

2010

Carticept, Inc.: Series B $20M

Posted in I - Series B, Q - 1Q10, R - SOUTH EAST, X - Device (Delivery), XX - GA

Carticept (Alpharetta, GA) a near commercial-stage medical device company focused on a computer controlled infusion system for osteoarthritis and cartilage injuries, closed a $20M Series B financing. Participants include SonoSite, Domain Associates and New Enterprise Associates.

Mar

2010

Rhythm Pharmaceuticals, Inc.: Series A $10M

Posted in I - Series A, Q - 1Q10, R - NORTH EAST, X - Diabetes, X - GI, X - Metabolism, X - Obesity, XX - MA

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage biopharmaceutical company whose peptide therapeutic agonists are focused on metabolic disorders, closed a $10M Series A financing. Participants include MPM Capital and New Enterprise Associates.

Feb

2010

PhaseBio Pharmaceuticals, Inc.: Series B $25M

Posted in I - Series B, Q - 1Q10, R - SOUTH EAST, X - Biologics Mfg., XX - NC

PhaseBio Pharmaceuticals (Research Triangle Park, NC) a development-stage biopharma company focused on elastin-like fusion proteins for improved expression and purification of biological, closed a $25M Series B financing. Participants include New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Development Corp. and Fletcher Spaght Ventures.

« Previous Entries

to top of page...